Turkish Validity and Reliability of the Parkinson's Disease Neuropsychometric Dementia Assessment Questionnaire in Individuals With Parkinson's Disease
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Nuray Alaca Alaca, Prof. Dr
- Telefonnummer: 05324251290
- E-Mail: nuraygeceralaca@gmail.com
Studienorte
-
-
Turkey
-
Istanbul, Turkey, Türkei (türkiye), +90
- Acibadem University
-
Kontakt:
- Nuray ALACA
- Telefonnummer: 05324251290
- E-Mail: nuray.alaca@acibadem.edu.tr
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
**Inclusion Criteria:**
- Clinical diagnosis of Parkinson's disease
- Hoehn and Yahr stage 1-3
- Age between 40 and 85 years
- Mini-Mental State Examination score ≥ 24
- Sufficient cognitive and communication ability to complete the assessments
- Attendance at the Movement Disorders Outpatient Clinic of the Neurology Department
- Willingness to participate in the study and provide written informed consent
**Exclusion Criteria:**
- Presence of a major psychiatric disorder, such as major depressive disorder or a psychotic disorder
- Diagnosis of advanced dementia
- Presence of an uncontrolled systemic chronic disease, such as uncontrolled diabetes mellitus or hypertension
- Presence of a severe cardiovascular or respiratory condition
- Presence of an additional orthopedic or neurological condition that may affect assessment performance
- Severe visual or hearing impairment that may interfere with the assessments
- Inability to cooperate adequately during the assessments
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Parkinson-Krankheit
|
Participants will complete the Turkish version of the Parkinson Neuropsychometric Dementia Assessment (PANDA) as part of the psychometric evaluation process.
The PANDA will be administered according to standardized instructions to assess cognitive performance in individuals with Parkinson's disease.
To evaluate test-retest reliability, the Turkish PANDA will be re-administered to a subgroup of participants after a predefined interval under similar conditions.
No therapeutic intervention will be provided as part of this methodological validation study.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Parkinson Neuropsychometric Dementia Assessment (PANDA) Total Score
Zeitfenster: [Time Frame: Baseline (at the time of PANDA administration)]
|
Cognitive performance will be assessed using the Turkish version of the Parkinson's Neuropsychometric Dementia Assessment (PANDA) in individuals with Parkinson's disease. The PANDA is a brief cognitive screening instrument specifically developed for Parkinson's disease and includes tasks assessing learning and memory, verbal fluency, visuospatial processing, working memory, and delayed recall. The PANDA total score ranges from 0 to 30, with higher scores indicating better cognitive performance. The psychometric properties of the Turkish version, including internal consistency, test-retest reliability, and construct validity, will be evaluated. |
[Time Frame: Baseline (at the time of PANDA administration)]
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Montreal Cognitive Assessment (MoCA) Total Score
Zeitfenster: [Time Frame: Baseline (at the time of cognitive assessment)]
|
Global cognitive performance will be assessed using the Montreal Cognitive Assessment (MoCA), a widely used cognitive screening tool that evaluates multiple cognitive domains, including attention, executive functions, memory, language, visuospatial abilities, abstraction, calculation, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance. MoCA scores will be used to evaluate the convergent construct validity of the Turkish version of the Parkinson Neuropsychometric Dementia Assessment (PANDA). |
[Time Frame: Baseline (at the time of cognitive assessment)]
|
|
Mini-Mental State Examination (MMSE) Total Score
Zeitfenster: [Time Frame: Baseline (at the time of cognitive assessment)]
|
General cognitive status will also be assessed using the Mini-Mental State Examination (MMSE), which evaluates orientation, registration, attention and calculation, recall, language, and visuospatial abilities. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance. MMSE scores will be examined in relation to PANDA scores to further assess the convergent construct validity of the Turkish version of the PANDA. |
[Time Frame: Baseline (at the time of cognitive assessment)]
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2026-10/436
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .